Bixiye
QP33-26 Update for New-to-Market Medical Drugs: lunsotogene parvec-cwha
Taariikhda uu dhaqangalayo Barnaamijka: May 13, 2026
Natiijooyinka Raadinta
Soo bandhiga 4151 - 4160 ee natiijooyinka 4303
Bixiye
QP32-26 Commercial and MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective July 1, 2026
Taariikhda uu dhaqangalayo Barnaamijka: May 13, 2026
Bixiye
QP31-26 MHCP Pharmacy Benefit Exclusion for Avlayah™ and Qivigy™
Taariikhda uu dhaqangalayo Barnaamijka: May 13, 2026
Bixiye
QP30-26 Commercial Pharmacy Benefit Exclusion for Avlayah™ and Qivigy™
Taariikhda uu dhaqangalayo Barnaamijka: May 13, 2026
Bixiye
QP38-26 MHCP Pharmacy Benefit Exclusion for Avopef™, Epioxa™ HD/Epioxa, Fesilty™, Midazolam, Photrexa®, and Wainua®
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP37-26 Commercial Pharmacy Benefit Exclusion for Epioxa™ HD/Epioxa, Fensolvi®, Fesilty™, Midazolam, Photrexa®, Wainua®, Zemaira®, and Zoladex®
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026
Bixiye
QP36-26 Commercial Pharmacy Benefit Exclusion for Select Medications
Taariikhda uu dhaqangalayo Barnaamijka: May 27, 2026